PDA vs BPC-157: A Research Comparison
Medical-review status: A licensed medical reviewer has not yet been assigned to this page. Until one is, the page is published as an editorial draft and is not presented as medically reviewed. See our medical review policy.
Quick answer
PDA is marketed as an arginate-salt form of BPC-157. BPC-157 has a preclinical (mostly animal) research base; PDA has no published studies of its own. Related does not mean equivalent — they can differ in stability, absorption, safety, and regulatory status.
BPC-157 has a preclinical evidence base; PDA has none of its own. They are not shown to be equivalent. (Animal or laboratory findings only. Does not prove effects in humans.)
How they relate
BPC-157 is a synthetic peptide studied mainly in animals. Pentadeca Arginate is sold as the same peptide sequence prepared as an arginate salt, with claims of improved stability. We found no published data confirming those claims.
Distinguish the forms
Comparisons should distinguish BPC-157 free base, BPC-157 acetate, arginate and other salts, compounded preparations, research-grade materials, and any FDA-approved drugs (there are none here).
Advertisement slot — inactive
Ads are not enabled until the site is editorially and technically ready.
What the evidence shows
Preclinical evidenceBPC-157 preclinical studies report effects in tendon and gastrointestinal healing models; reviews judge the human evidence minimal.[1],[2],[3]
No direct evidence identifiedPDA itself has no peer-reviewed studies, so any claim about PDA is an extrapolation from BPC-157.[4]
Why "related" is not "equivalent"
A salt change can alter solubility, stability, and absorption, and neither PDA nor BPC-157 has been shown safe and effective in humans. Treating BPC-157 data as proof about PDA is not scientifically justified.
Regulatory and anti-doping status
Neither is FDA-approved. BPC-157 is on the World Anti-Doping Agency Prohibited List (class S0); PDA’s status can differ and change, and athletes must verify current rules.[5],[6]
Frequently asked questions
Is PDA just BPC-157?
PDA is marketed as an arginate-salt form of BPC-157, but they are not proven equivalent, and PDA has no studies of its own.
Which is better?
Neither is proven safe or effective in humans, so "better" cannot be established from the current evidence.
References
4 peer-reviewed journal sources and 2 additional authoritative references. Every reference supports a specific statement above.
- [1] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JS (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology, 110(3):774–780. View source Peer-reviewed journal
- [2] Gwyer D, Wragg NM, Wilson SL (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2):153–159. View source Peer-reviewed journal
- [3] Vasireddi N, Hahamyan H, Salata MJ, et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS Journal (SAGE), Systematic review. View source Peer-reviewed journal
- [4] Current Reviews in Musculoskeletal Medicine (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, Narrative review. View source Peer-reviewed journal
- [5] Operation Supplement Safety (U.S. Department of Defense) (2024). BPC-157: a prohibited peptide and an unapproved drug found in health and wellness products. OPSS.org (DoD), U.S. government consumer-safety advisory. View source Government / regulatory
- [6] U.S. Food and Drug Administration (2025). Bulk drug substances used in compounding under section 503A of the FD&C Act. FDA.gov, Regulatory information (compounding). View source Government / regulatory